Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.16 USD | +3.69% | -17.46% | +311.56% |
Business Summary
Number of employees: 68
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Immunotherapies
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 17-05-31 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 18-04-30 | |
Charles Winter
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Andy Meyer
IRC | Investor Relations Contact | 40 | 21-02-28 |
James Pennington
LAW | General Counsel | - | - |
Human Resources Officer | - | 22-09-22 | |
Byron Robinson
PRN | Corporate Officer/Principal | 59 | 22-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 21-03-17 |
Jay Lichter
CHM | Chairman | 62 | 17-05-31 |
Ronald Barrett
BRD | Director/Board Member | 68 | 21-09-06 |
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Alana McNulty
BRD | Director/Board Member | 61 | 21-09-06 |
Sheila Gujrathi
BRD | Director/Board Member | 53 | 21-03-17 |
Winston Kung
BRD | Director/Board Member | 48 | 22-09-21 |
Jake Simson
BRD | Director/Board Member | 38 | 21-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 51,856,438 | 46,965,412 ( 90.57 %) | 5,771 ( 0.0111 %) | 90.57 % |
Company contact information
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway Suite 200
92130, San Diego
+
http://www.januxrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+311.56% | 2.29B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- JANX Stock
- Company Janux Therapeutics, Inc.